Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy.

Abstract excerpt

Patients with Duchenne muscular dystrophy (DMD), an X-linked lethal muscle-wasting disease, have abnormal expression of the protein dystrophin within their muscle fibres. In the mdx mouse model of this condition, both germline and neonatal somatic gene transfers of dystrophin cDNAs have demonstrated the potential of gene therapy in treating DMD. However, in many DMD patients, there appears to be no dystrophin...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dystrophin
• Share to DMD gene
• Share to Genetic Therapy